N H Ogden1, J K Koffi1, L R Lindsay2, S Fleming3, D C Mombourquette3, C Sanford4, J Badcock5, R R Gad5, N Jain-Sheehan6, S Moore6, C Russell6, L Hobbs6, R Baydack7, S Graham-Derham7, L Lachance8, K Simmonds8, A N Scott8. 1. Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada, Ottawa, ON. 2. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB. 3. Public Health Branch, Nova Scotia Department of Health and Wellness, Halifax, NS. 4. Population Health Assessment and Surveillance, Prince Edward Island Department of Health and Wellness, Charlottetown, PE. 5. Office of the Chief Medical Officer of Health, New Brunswick Department of Health, NB. 6. Enteric, Zoonotic and Vector-Borne Diseases, Public Health Ontario, Toronto, ON. 7. Communicable Disease Control Branch, Manitoba Health Healthy Living and Seniors, Winnipeg, MB. 8. Surveillance and Assessment Branch, Alberta Health, Calgary, AB.
Abstract
OBJECTIVES: To summarize the first four years of national surveillance for Lyme disease in Canada from 2009 to 2012 and to conduct a preliminary comparison of presenting clinical manifestations in Canada and the United States. METHODS: The numbers and incidence of reported cases by province, month, year, age and sex were calculated. Logistic regression was used to examine trends over time. Acquisition locations were mapped and presenting clinical manifestations reported for jurisdictions where data was available. Variations by province, year, age and sex as well as presenting clinical symptoms were explored by logistic regression. An initial comparative analysis was made of presenting symptoms in Canada and the United States. RESULTS: The numbers of reported cases rose significantly from 144 in 2009 to 338 in 2012 (coefficient = 0.34, standard error = 0.07, P <0.05), mostly due to an increased incidence of infections acquired in Canada. More cases were classified as 'confirmed' (71.5%) than 'probable' (28.5%). Most cases occurred in locations where vector tick populations were known to be present. More men than women were affected (53.4% versus 46.6%), incidence was highest in adults aged 55 to 74 years and in children aged five to 14 years. Most cases (95%) were acquired from April to November. Of cases acquired in endemic areas, 39.7% presented with manifestations of early Lyme disease, while 60.3% had manifestations of disseminated Lyme disease. There were significant differences among age groups, sexes and provinces in the frequencies of reported clinical manifestations. The proportion of cases acquired in endemic areas presenting with early Lyme disease was lower than that reported in the US. CONCLUSION: Lyme disease incidence is increasing in Canada. Most cases are acquired where vector tick populations are spreading and this varies geographically within and among provinces. There is also variation in the frequency of age, season and presenting manifestations. The lower proportion of cases presenting with early Lyme disease in Canada compared with the US suggests lower awareness of early Lyme disease in Canada, but this requires further study.
OBJECTIVES: To summarize the first four years of national surveillance for Lyme disease in Canada from 2009 to 2012 and to conduct a preliminary comparison of presenting clinical manifestations in Canada and the United States. METHODS: The numbers and incidence of reported cases by province, month, year, age and sex were calculated. Logistic regression was used to examine trends over time. Acquisition locations were mapped and presenting clinical manifestations reported for jurisdictions where data was available. Variations by province, year, age and sex as well as presenting clinical symptoms were explored by logistic regression. An initial comparative analysis was made of presenting symptoms in Canada and the United States. RESULTS: The numbers of reported cases rose significantly from 144 in 2009 to 338 in 2012 (coefficient = 0.34, standard error = 0.07, P <0.05), mostly due to an increased incidence of infections acquired in Canada. More cases were classified as 'confirmed' (71.5%) than 'probable' (28.5%). Most cases occurred in locations where vector tick populations were known to be present. More men than women were affected (53.4% versus 46.6%), incidence was highest in adults aged 55 to 74 years and in children aged five to 14 years. Most cases (95%) were acquired from April to November. Of cases acquired in endemic areas, 39.7% presented with manifestations of early Lyme disease, while 60.3% had manifestations of disseminated Lyme disease. There were significant differences among age groups, sexes and provinces in the frequencies of reported clinical manifestations. The proportion of cases acquired in endemic areas presenting with early Lyme disease was lower than that reported in the US. CONCLUSION: Lyme disease incidence is increasing in Canada. Most cases are acquired where vector tick populations are spreading and this varies geographically within and among provinces. There is also variation in the frequency of age, season and presenting manifestations. The lower proportion of cases presenting with early Lyme disease in Canada compared with the US suggests lower awareness of early Lyme disease in Canada, but this requires further study.
Authors: R C Falco; D F McKenna; T J Daniels; R B Nadelman; J Nowakowski; D Fish; G P Wormser Journal: Am J Epidemiol Date: 1999-04-15 Impact factor: 4.897
Authors: Klaus Kurtenbach; Klára Hanincová; Jean I Tsao; Gabriele Margos; Durland Fish; Nicholas H Ogden Journal: Nat Rev Microbiol Date: 2006-08-07 Impact factor: 60.633
Authors: Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: Allison L Naleway; Edward A Belongia; James J Kazmierczak; Robert T Greenlee; Jeffrey P Davis Journal: Am J Epidemiol Date: 2002-06-15 Impact factor: 4.897
Authors: Katie M Clow; Patrick A Leighton; Nicholas H Ogden; L Robbin Lindsay; Pascal Michel; David L Pearl; Claire M Jardine Journal: PLoS One Date: 2017-12-27 Impact factor: 3.240
Authors: Salima Gasmi; Catherine Bouchard; Nicholas H Ogden; Ariane Adam-Poupart; Yann Pelcat; Erin E Rees; François Milord; Patrick A Leighton; Robbin L Lindsay; Jules K Koffi; Karine Thivierge Journal: PLoS One Date: 2018-08-22 Impact factor: 3.240
Authors: Holly Burrows; Benoit Talbot; Roman McKay; Andreea Slatculescu; James Logan; Charles Thickstun; L Robbin Lindsay; Antonia Dibernardo; Jules K Koffi; Nicholas H Ogden; Manisha A Kulkarni Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240
Authors: S Gasmi; N H Ogden; L R Lindsay; S Burns; S Fleming; J Badcock; S Hanan; C Gaulin; M A Leblanc; C Russell; M Nelder; L Hobbs; S Graham-Derham; L Lachance; A N Scott; E Galanis; J K Koffi Journal: Can Commun Dis Rep Date: 2017-10-05